文献速递脑血管病头痛与眩晕

CGRP抑制剂与偏头痛患者心血管事件:回顾性观察队列研究

Calcitonin Gene-Related Peptide Inhibitors and Cardiovascular Events in Patients With Migraine: A Retrospective, Observational Cohort Study.
PubMed 文献 · Neurology · 2026-01-07

该回顾性观察队列研究基于MarketScan保险索赔数据,纳入900,370例偏头痛患者,其中58,679例启动CGRP抑制剂。倾向评分重叠加权分析显示,启动CGRP抑制剂者主要心血管复合终点发生率更高(8.77 vs 6.76事件/1000人年;aHR 1.26,95%CI 1.10-1.45),缺血性卒中风险亦升高(aHR 1.26,95%CI 1.07-1.49)。

要点

  • 偏头痛患者启动CGRP抑制剂与主要心血管复合终点风险轻度增加相关(aHR 1.26)。
  • 缺血性卒中风险显著升高(aHR 1.26),但心肌梗死、血运重建等无显著关联。
  • 启动CGRP抑制剂者基线心血管疾病负担高于未启动者,需谨慎解读。

核心结论

  • 在偏头痛患者中,启动CGRP抑制剂与心血管事件复合终点风险轻度增加相关。

研究设计与样本

  • 回顾性观察队列研究,使用MarketScan保险索赔数据,纳入至少一次偏头痛诊断相关索赔且诊断前连续覆盖≥12个月的受益人。
  • 共纳入900,370例受益人(中位年龄41岁,77.8%女性),其中58,679例启动CGRP抑制剂,841,691例未启动。
  • 采用序贯试验框架,计算粗率和倾向评分重叠加权队列中的心血管事件率,并计算调整风险比(HR)及95%CI。

主要发现

  • 重叠加权分析中,启动CGRP抑制剂者主要终点发生率为8.77事件/1000人年,未启动者为6.76事件/1000人年(aHR 1.26,95%CI 1.10-1.45)。
  • 启动CGRP抑制剂与缺血性卒中风险显著升高相关(aHR 1.26,95%CI 1.07-1.49)。
  • 心肌梗死、血运重建、视网膜中央动脉闭塞和颅内出血等其他次要终点无显著关联。
  • 启动CGRP抑制剂者基线心血管疾病负担高于未启动者。

临床怎么用

  • 处方CGRP抑制剂时应评估患者基线心血管风险,尤其关注缺血性卒中风险。
  • 对已有心血管疾病负担的偏头痛患者,启动CGRP抑制剂需权衡获益与风险。

局限性

  • 回顾性观察设计,可能存在残余混杂。
  • 使用索赔数据,事件 ascertainment 可能不完整。
  • 启动CGRP抑制剂者基线心血管疾病负担更高,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Calcitonin gene-related peptide (CGRP) inhibitors have entered widespread use in the United States for treatment of migraine, but data on their cardiovascular risk profile are lacking. The objective of this study was to determine whether exposure to a CGRP inhibitor is associated with cardiovascular events in patients with migraine. METHODS: A retrospective, observational, cohort study was conducted using computerized claims data from a proprietary, insurance-based registry, MarketScan (by Merative). Beneficiaries with at least one claim related to a migraine diagnosis and continuous coverage for at least 12 months before migraine diagnosis were included. Using a sequential trial framework, the rate of cardiovascular events was computed in those who did and did not initiate a CGRP inhibitor, using both crude estimates and those derived in propensity score overlap-weighted cohorts. Adjusted hazard ratios (HR) and corresponding 95% CI were computed. The principal exposure was initiation of any CGRP inhibitor. The primary end point was a composite of myocardial infarction (MI), cerebral ischemic stroke, revascularization, peripheral arterial disease, or central retinal artery occlusion (CRAO). Secondary end points included each component individually. A falsification end point (humeral fracture) was included. RESULTS: In total, 900,370 beneficiaries (median age 41 [Q1, Q3: 31, 51] years; 77.8% female) were included, of whom 58,679 initiated a CGRP inhibitor and 841,691 did not initiate a CGRP inhibitor during the study period. Beneficiaries initiating a CGRP inhibitor exhibited a greater degree of cardiovascular morbidity at baseline than noninitiators. In the overlap-weighted analysis, there was a higher rate of the primary end point among beneficiaries who initiated a CGRP inhibitor (8.77 events/1,000 person-years vs 6.76 events/1,000 person-years; aHR 1.26 [95% CI 1.10-1.45]). Initiation of a CGRP inhibitor was associated with a significantly higher rate of one secondary end point (ischemic stroke [aHR 1.26 (95% CI 1.07-1.49)]) but not 4 other secondary end points: MI, revascularization, CRAO, and intracranial hemorrhage. DISCUSSION: In a nationwide cohort study, initiation of a CGRP inhibitor was associated with an increased risk of a composite of cardiovascular events; however, the magnitude of the increased risk was low. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with migraine, initiation of a CGRP inhibitor was associated with a modestly increased risk of a composite of cardiovascular events.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lusk JB, Wilson LE, Moore C, et al. Calcitonin Gene-Related Peptide Inhibitors and Cardiovascular Events in Patients With Migraine: A Retrospective, Observational Cohort Study. Neurology. 2026. PMID: 41499728. doi:10.1212/WNL.0000000000214479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。